Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Zentalis Pharmaceuticals, Inc. (ZNTL)
|
Add to portfolio |
|
|
|
| Price: |
$78.69
| | Metrics |
| OS: |
70.6
|
M
| |
|
|
| Market cap: |
$5.56
|
B
| |
|
|
|
Net cash:
|
$267
|
M
| |
$3.78
|
per share
|
|
EV:
|
$5.29
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue growth | | | -100.0% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 18.9 |
| Gross profit | 0.0 | 0.0 | 0.0 | -18.9 |
| Gross margin | | | | -135050.0% |
| Research and development | 175.6 | 84.9 | 38.4 | |
| General and administrative | 40.9 | 33.9 | 8.5 | 4.9 |
| EBIT | -163.1 | -118.8 | -46.8 | -23.8 |
| EBIT margin | | | | -169878.6% |
| Pre-tax income | -164.6 | -118.1 | -46.4 | -23.4 |
| Income taxes | -0.3 | 0.4 | 0.0 | 0.0 |
| Tax rate | 0.2% | | | |
| Net income | -158.7 | -117.8 | -45.7 | -23.4 |
| Net margin | | | | -167371.4% |
| |
| Diluted EPS | ($3.72) | ($4.19) | ($8.16) | |
| Shares outstanding (diluted) | 42.7 | 28.1 | 5.6 | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|